TrialDigestive diseases and sciences2024

A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.

Reinier C A van Linschoten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.